| __timestamp | Eli Lilly and Company | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4733600000 | 22223073 |
| Thursday, January 1, 2015 | 4796400000 | 6966842 |
| Friday, January 1, 2016 | 5243900000 | 9000499 |
| Sunday, January 1, 2017 | 5281800000 | 13741186 |
| Monday, January 1, 2018 | 5051200000 | 19040000 |
| Tuesday, January 1, 2019 | 5595000000 | 23559000 |
| Wednesday, January 1, 2020 | 6085700000 | 31931000 |
| Friday, January 1, 2021 | 7025900000 | 44981000 |
| Saturday, January 1, 2022 | 7190800000 | 54234000 |
| Sunday, January 1, 2023 | 9313400000 | 63806000 |
| Monday, January 1, 2024 | 14271000000 |
Igniting the spark of knowledge
In the competitive world of biopharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Eli Lilly and Company has consistently outpaced Viking Therapeutics, Inc. in R&D investments. From 2014 to 2023, Eli Lilly's R&D expenses surged by nearly 97%, reaching a peak in 2023. This reflects their strategic focus on expanding their drug pipeline and enhancing therapeutic offerings. In contrast, Viking Therapeutics, while showing a steady increase in R&D spending, grew by approximately 187% over the same period, albeit from a much smaller base. This growth underscores Viking's ambition to carve out a niche in the industry. The disparity in R&D spending highlights the different scales and strategies of these companies, with Eli Lilly leveraging its resources for broad innovation, while Viking focuses on targeted advancements.
Who Prioritizes Innovation? R&D Spending Compared for Eli Lilly and Company and Alnylam Pharmaceuticals, Inc.
Comparing Innovation Spending: Eli Lilly and Company and Biogen Inc.
Eli Lilly and Company vs Blueprint Medicines Corporation: Strategic Focus on R&D Spending
Research and Development Investment: Eli Lilly and Company vs Catalyst Pharmaceuticals, Inc.
R&D Insights: How Eli Lilly and Company and Protagonist Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Eli Lilly and Company and Galapagos NV
R&D Insights: How Johnson & Johnson and Viking Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: GSK plc vs Viking Therapeutics, Inc.
R&D Spending Showdown: Takeda Pharmaceutical Company Limited vs Viking Therapeutics, Inc.
argenx SE or Viking Therapeutics, Inc.: Who Invests More in Innovation?
Incyte Corporation vs Viking Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Viking Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.